Natco gets CDSCO nods for Baricitinib drug for COVID treatment, Stock Rise

May 03 2021 11:30 AM
Natco gets CDSCO nods for Baricitinib drug for COVID treatment, Stock Rise

India’s leading drug major Natco Pharma Limited on Monday said that the Company received emergency use approval for Baricitinib tablets, for the treatment of coronavirus-positive patients, from India’s Central Drugs Standard Control Organization (CDSCO).

In its regulatory filing, the company officially stated: ''Natco Pharma Ltd has received emergency use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.,''

Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.

Reacting to the development, Shares of Natco Pharma Ltd, during the mid-noon session was trading in NSE at Rs.927 per share up by Rs. 30.70 from the previous close of Rs. 896.35. In comparison, the NSE Nifty 14,555, down by 76 points in trade.

Credit Line Guarantee Scheme: Hospitality sector pushes for govt for ECLGS

Centre may launch reverse auction system for supplying rails to Railways

What to watch out for Markets this week, Election Results focus